The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer☆☆☆

Tirino, Virginia; Camerlingo, Rosa; Franco, Renato; Malanga, Donatella; Rocca, Antonello La; Viglietto, Giuseppe; Rocco, Gaetano; Pirozzi, Giuseppe

doi:10.1016/j.ejcts.2009.03.063

Cited by 193 publications

(174 citation statements)

References 17 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…CD44 + /CD24 + and CD44 + /CD24 -/low subpopulations derived from cell line A549 were characterized using their colony-and sphere-formation potential. CD133 is the most commonly reported cell surface marker that has been used to isolate CSCs from lung cancer cell lines and fresh tumor samples, but there is no consensus on the level of CD133 expression in cell line A549 [7,12,[32][33][34][35][36]. Our data demonstrate that 0.94% of A549 cells expressed the CD133 marker.…”

Section: Discussionmentioning

confidence: 68%

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

Roudi

Madjd

Ebrahimi

et al. 2014

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

Abstract:Cancer stem cells (CSCs) are subpopulations of tumor cells that are responsible for tumor initiation, maintenance and metastasis. Recent studies suggested that lung cancer arises from CSCs. In this study, the expression of potential CSC markers in cell line A549 was evaluated. We applied flow cytometry to assess the expression of putative stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), CD24, CD44, CD133 and ABCG2. Cells were then sorted according to the expression of CD44 and CD24 markers by fluorescence-activated cell sorting (FACS) Aria II and characterized using their -/low subpopulations were 84.37 ± 2.86% and 90 ± 3.06%, respectively, while the parental A549 cells yielded 56.65 ± 2.33% using the colony-formation assay. Both isolated subpopulations formed spheres in serumfree medium supplemented with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). CD44 and CD24 cannot be considered potential markers for isolating lung CSCs in cell line A549, but further investigation using in vivo assays is required.

show abstract

Section: Discussionmentioning

confidence: 68%

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

Roudi

Madjd

Ebrahimi

et al. 2014

Cellular and Molecular Biology Letters

View full text Add to dashboard Cite

show abstract

“…+ cells and A549 cells may be due to unique characteristic of CD133 + cells [22][23][24]. It need to be noticed that Meng et al studied the CD133 + and CD133 -A549 cells and found that they exhibited similar abilities of colony formation, invasion [16].…”

Section: Discussionmentioning

confidence: 99%

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

Zhang¹,

Yang²,

Sun³

et al. 2014

neo

View full text Add to dashboard Cite

Lung cancer remains a major cause of cancer-related lethality because of high incidence and recurrence in spite of significant advances in staging and therapy. In present study, we identified a subpopulation of cells isolated from the A549 cell line with marker CD133. In vivo results showed that A549 CD133 + cells displayed high liver metastatic potential. Severe liver cell damage with tumor cell invasion revealed by pathological examination and these changes were consistent with the results of serological tests where the plasma GPT and GOT level are significantly higher than that of the control group. Compared with A549 cells, A549 CD133 + cells expressed high levels of VEGF and exhibited high migration and invasion capability. In conclusion, we first reported that A549 CD133 + cells exhibited characteristic of high liver metastatic potential which makes it be a suitable model for further study of liver metastasis of lung adenocarcinoma and provide a potential platform for antimetastatic drug discovery or evaluation. Key words: human lung adenocarcinoma, liver metastasis, migration, invasion, CD133Lung cancer is one of the most aggressive neoplasms in the world [1]. Despite management and treatment of lung cancer has been improved these years, but the prognosis remains poor, the 5-year survival rate of non-small cell lung cancer (NSCLC) is no more than 15 % [2]. Approximately 50 % of NSCLC patients with stage I and II will die from recurrent disease despite conventional therapy, and nearly 70% of lung cancer patients will die from metastatic disease, even after surgical resection of the primary tumor, radiation therapy, and chemotherapy [3]. Thus, it is important to find novel effective therapies to inhibit lung cancer metastasis.The most common four metastatic sites of patients with solitary metastatic NSCLC were: bone, liver, kidney and spleen [3]. Nevertheless, the mechanism of which lung adenocarcinoma selectively disseminated to certain organs remains unknown. However, experimental reproducible animal models facilitate to understand the process of metastasis and can provide suitable models for basic or preclinical studies.Different kinds of cancer metastasis model have been published yet. Early in 1996, Iguchi H et al [4] have established lung cancer metastasis model with human lung squamous cell carcinoma-derived cells (HARA). In 1959, Leduc [5] was the first to describe liver metastasis in mice after injection of hepatoma carcinoma cells in the spleen. Moreover, the liver metastasis models in nude mice of colon carcinoma have been successfully established [6,7]. Early studies in immunodeficient mice illustrated that subcutaneous injection of tumor cells seldom give rise to liver metastases [8].However, no lung adenocarcinoma liver metastasis model has been published so far. CD133 as a marker of cancer stem cells (CSCs) has been demonstrated in many cancers including lung cancer [9][10][11][12][13]. The CSCs theory indicated that subpopulation of tumor cells with stem or progenitor cell characteristics c...

show abstract

“…The high expression of CD133 in ccRCC with favorable clinicopathological characteristics was an unexpected result, as CD133 has been applied as a putative CSC marker in numerous malignant tumors, and its high expression has been considered a poor prognostic factor. CD133 is currently applied as a cell-surface marker to isolate CSCs in malignant tumors of the colon, brain, lung, prostate, pancreas, liver, stomach and uterus (11,(25)(26)(27). A CD133…”

Section: Discussionmentioning

confidence: 99%

High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis

Cho

2011

Oncol Lett

View full text Add to dashboard Cite

Abstract. The cancer stem cell (CSC) model suggests that high levels of CSCs within a tumor are associated with poor prognosis. The aim of this study was to investigate the expression of the stem cell marker CD133 in clear cell renal cell carcinoma (ccRCC), and its prognostic significance. The expression of CD133 was examined in 140 cases of ccRCC using immunohistochemistry. Ki-67 and Oct-4 were doubleimmunostained with CD133 to evaluate the proliferative activity and the stemness of CD133-expressing cells, respectively. CD133 expression was observed in 45 cases (32.1%) and high levels of expression were found to be associated with a macro-/microcystic pattern, non-sarcomatoid changes and non-metastatic disease. The Ki-67 labeling index tended to be lower in CD133-expressing ccRCCs compared to nonexpressing tumors. CD133-expressing tumor cells rarely expressed Oct-4. A high degree of CD133 expression was observed in ccRCC with more differentiated morphology and non-metastatic disease, suggesting that CD133 is a favorable prognostic marker. These results also indicate that CD133 as a single marker may not be sufficient for CSC identification in ccRCC and, therefore, more specific CSC markers should be developed.

show abstract

The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer☆☆☆

Abstract: We have isolated and characterised a population of CD133-positive cells from NSCLC that is able to give rise to spheres and can act as tumour-initiating cells.

Cited by 193 publications

References 17 publications

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential

High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis

Contact Info

Product

Resources

About